ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Details Narrative 1)

Notes Payable (Details Narrative 1)			1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	13 Months Ended
Notes Payable (Details Narrative 1)	Sep. 02, 2016 USD ($)	Jun. 30, 2016 USD ($) shares	Aug. 31, 2016 USD ($) shares	Nov. 30, 2010 USD ($) Number shares	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Aug. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Common stock fair value				$ 2,775,300
Unamortized discount					$ 2,142,188		$ 2,142,188
Reduction in warrants from debt conversions								$ (1,207,813)
Loss on restructuring of debt						$ (933,134)		(811,909)
June 2016 Amendments [Member] \| 12% Junior Secured Notes Payable 2014 [Member]
Debt Instrument [Line Items]
Debt face amount						1,500,000		1,500,000
Number of warrants issued \| shares		11,250
Second Amendment (2016 PIPE) [Member]
Debt Instrument [Line Items]
Reduction in warrants from debt conversions	$ 1,207,813
Second Amendment (2016 PIPE) [Member] \| 12% Junior Secured Notes Payable 2014 [Member]
Debt Instrument [Line Items]
Debt face amount			$ 1,750,000
Number of warrants issued \| shares			13,125
Loss on restructuring of debt										$ 933,000
Non-Employee Directors [Member]
Debt Instrument [Line Items]
Number of unit issued \| shares				14,180
Number of officers and directors \| Number				3
Value of unit issued \| shares				158,816
Officer [Member]
Debt Instrument [Line Items]
Number of unit issued \| shares				22,068
Number of officers and directors \| Number				4
Value of unit issued \| shares				247,164
2010 Junior Secured Notes Payable [Member]
Debt Instrument [Line Items]
Description of unit				Units consisting of a junior secured note (the “2010 Secured Notes”) and one share of the Company’s common stock.
Number of unit issued \| shares				267,857
Stated interest rate				3.50%
Description of collateral terms				Collateralized by a security interest in all of the assets of the Company, which security interest is junior and subordinate to the security interests that collateralize the Brainlab Note and the 2014 Secured Notes.
Description of payment terms				Interest on the 2010 Secured Notes will be due and payable in a single payment upon maturity.
Unamortized discount					$ 2,060,865		$ 2,060,865				$ 2,302,472
Interest expense terms				10-year term of the notes using the effective interest method.
Proceeds from debt issuance				$ 3,000,000
Maturity date				Nov. 30, 2020
New Brainlab Note [Member] \| June 2016 Amendments [Member]
Debt Instrument [Line Items]
Debt face amount						500,000		500,000
Number of warrants issued \| shares		34,957
New Brainlab Note [Member] \| Non-Employee Directors [Member] \| June 2016 Amendments [Member]
Debt Instrument [Line Items]
Debt face amount						$ 3,000,000		$ 3,000,000
Brainlab Senior Secured Note Payable [Member]
Debt Instrument [Line Items]
Debt face amount									$ 5,000,000
Stated interest rate									5.50%
Maturity date									Apr. 30, 2016
Brainlab Senior Secured Note Payable [Member] \| 12% Junior Secured Notes Payable 2014 [Member]
Debt Instrument [Line Items]
Loss on restructuring of debt		$ 820,000